ImPact Biotech Presents Additional Interim Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer


TEL AVIV, Israel, June 02, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced additional efficacy and safety data from ENLIGHTED (ENdoluminal LIGHT ActivatED), its ongoing pivotal Phase 3 clinical trial evaluating Padeliporfin VTP in patients with low-grade UTUC. The interim results, which demonstrate Padeliporfin VTP treatment was well-tolerated alongside further efficacy, are being presented today in a poster session at the American Society of Clinical Oncology 2024 Annual Meeting in Chicago, Illinois.

View post:
ImPact Biotech Presents Additional Interim Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer

Related Posts